Glucagon use by U.S. adults with type 1 and type 2 diabetes

Peter A. Kahn, Shuling Liu, Rozalina McCoy, Robert A. Gabbay, Kasia Lipska

Research output: Contribution to journalArticlepeer-review


The American Diabetes Association recommends that all patients at risk for hypoglycemia be prescribed glucagon. Despite this recommendation, there is evidence that prescription rates are lower than expected for patients with type 1 and type 2 diabetes. This study investigated prescription patterns for glucagon among de-identified administrative claims from OptumLabs® Data Warehouse for prescriptions between January 1, 2014 and December 31, 2014 among pharmacologically treated type 1 and 2 diabetes patients. We find that glucagon was rarely filled by patients with type 1 and type 2 diabetes, including fewer than 5% of patients with prior hypoglycemia requiring emergency healthcare utilization. Among patients with type 1 diabetes, glucagon fills were unpredictable and not targeted to highest risk patients.

Original languageEnglish (US)
Article number107882
JournalJournal of Diabetes and its Complications
Issue number5
StatePublished - May 2021


  • Adverse drug events
  • Glucagon
  • Hypoglycemia
  • Type 1 diabetes
  • Type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'Glucagon use by U.S. adults with type 1 and type 2 diabetes'. Together they form a unique fingerprint.

Cite this